La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Harbin Pharmaceutical Group Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	2.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

Jun 25

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

May 25

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Apr 17

AMMINISTRATORE DELEGATO

Harbin Pharmaceutical Group non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Bo Jiang	CFO & VP	3.6yrs	CN¥1.31m	Nessun dato
Xiaodong Meng	VP & Secretary	less than a year	CN¥1.31m	0.013% CN¥ 1.1m
Haitao Jiang	Vice President	2.3yrs	CN¥691.90k	0.0019% CN¥ 157.3k
Jicheng Xia	Vice President	1.8yrs	CN¥467.60k	0.0032% CN¥ 261.9k
Bangdong Li	Vice President	1.8yrs	CN¥578.60k	0.0016% CN¥ 130.9k

1.8yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di 600664 non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Aidong Lou	Independent Director	3.6yrs	CN¥150.00k	Nessun dato
Weihong Lu	Independent Director	3.6yrs	CN¥150.00k	Nessun dato
Zhaohua Li	Independent Director	3.6yrs	CN¥150.00k	Nessun dato
Ying Lei	Independent Director	less than a year	Nessun dato	Nessun dato
Xiaoping Hu	Chairman	3.6yrs	Nessun dato	Nessun dato
Shiwei Yin	Director	2.5yrs	Nessun dato	Nessun dato
Zhifeng Sun	Director	2.2yrs	Nessun dato	Nessun dato
Fangju Qiu	Employee Supervisor	less than a year	Nessun dato	0.000080% CN¥ 6.6k
Liu Mo	Director	less than a year	Nessun dato	Nessun dato
Cheng Peng	Supervisor	less than a year	Nessun dato	Nessun dato
Wenguang Peng	Chairman of the Supervisory Board	less than a year	Nessun dato	Nessun dato

2.2yrs

Durata media

49yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 600664 non è considerato esperto (durata media del mandato 2.2 anni), il che suggerisce un nuovo consiglio.

Harbin Pharmaceutical Group Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new and inexperienced directors

Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

High number of new and inexperienced directors

Investor sentiment improves as stock rises 18%

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024

First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.05 in 1Q 2023)

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 18%

Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024

Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)

Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)

Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) dropped from S&P Global BMI Index

New 90-day low: CN¥2.84

New 90-day low: CN¥3.09

New 90-day low: CN¥3.22

Third quarter earnings released

New 90-day low: CN¥3.33

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media